CEO Jensen Huang reiterated what he has been saying out loud all this time, although this time his words were a little bit ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Background Lynch syndrome (LS) is the most common hereditary cause of colorectal cancer (CRC) and results from pathogenic germline variants affecting mismatch repair. The tissue microenvironment that ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

Advances in light sheet fluorescence microscopy (LSFM) and tissue clearing have enabled 3D imaging of intact tissue samples; however, the analytical tools for processing these datasets have lagged ...

Recently, a friend asked me a question that's been floating around every boardroom and business school: "With AI writing code, does programming still matter?" It's a fair question. Generative AI can ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...